SLU-PP-332 Benefits: Claims vs What Studies Show
Benefits people claim for SLU-PP-332, set against what published studies measured, and where no study exists.
- Strongest evidence
- Animal
- Human / animal studies
- 0 / 4
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- research chemical
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Energy | Animal evidence, 2 of 4 | 0 / 3 | Energy expenditure and fatty acid oxidation; Exercise endurance; Mitochondrial function in muscle cells | Evidence for energy |
| Metabolism | Animal evidence, 2 of 4 | 0 / 1 | Energy expenditure and fatty acid oxidation; Fat mass and insulin sensitivity | Evidence for metabolism |
| Weight loss | Animal evidence, 2 of 4 | 0 / 1 | Energy expenditure and fatty acid oxidation; Fat mass and insulin sensitivity | Evidence for weight loss |
| Longevity | Animal evidence, 2 of 4 | 0 / 2 | Aging kidney; Myoblast markers and differentiation | Evidence for longevity |
| Diabetes | Animal evidence, 2 of 4 | 0 / 1 | Fat mass and insulin sensitivity | Evidence for diabetes |
| Heart health | Animal evidence, 2 of 4 | 0 / 1 | Heart failure model | Evidence for heart health |
| Athletes | Animal evidence, 2 of 4 | 0 / 1 | Exercise endurance | Evidence for athletes |
| Inflammation | Animal evidence, 2 of 4 | 0 / 1 | Aging kidney | Evidence for inflammation |
| Strength | In vitro evidence, 1 of 4 | 0 / 1 | Myoblast markers and differentiation | Evidence for strength |
Strongest study per claim: Energy, The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806; Metabolism, The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806; Weight loss, The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Evidence base is preclinical | The review states clinical trials are needed to confirm efficacy and safety in humans. | Systematic review | Revista medica de Chile 2026, PMID 42024694 |
| Energy expenditure and fatty acid oxidation | In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Fat mass and insulin sensitivity | The ERR agonist reduced obesity and improved insulin sensitivity in mouse models of metabolic syndrome. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Heart failure model | SLU-PP-332 and SLU-PP-915 improved ejection fraction, reduced fibrosis and increased survival in a mouse heart failure model. | Animal · mouse (plus cell experiments) (not a human result) | Circulation 2024, PMID 37961903 |
| Exercise endurance | In mice, SLU-PP-332 increased type IIa oxidative skeletal muscle fibers and enhanced exercise endurance. | Animal · mouse (plus a skeletal muscle cell line) (not a human result) | ACS chemical biology 2023, PMID 36988910 |
| Mitochondrial function in muscle cells | SLU-PP-332 increased mitochondrial function and cellular respiration in a skeletal muscle cell line. | Animal · mouse (plus a skeletal muscle cell line) (not a human result) | ACS chemical biology 2023, PMID 36988910 |
| Aging kidney | An 8-week pan-ERR agonist treatment reversed age-related albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines in aged mice. | Animal · mouse (not a human result) | The American journal of pathology 2023, PMID 37717940 |
| In vitro metabolites | 22 in vitro metabolites were identified; eight (M1, M7, M9, M10, M13, M14, M19, M20) were the most abundant. | In vitro (not a human result) | Drug testing and analysis 2026, PMID 41688415 |
| Myoblast markers and differentiation | In myoblasts from inactive women, SLU-PP-332 down-regulated NOX4 and up-regulated SIRT1, PGC-1α, ERRα, FNDC5, Akt and Bcl-2, reducing oxidative stress and senescence markers. | In vitro (not a human result)n = 20 | Frontiers in physiology 2025, PMID 40692696 |
Fat loss and blood sugar claims: mouse data
In diet-induced obese and ob/ob mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation and lowered fat mass accumulation.[2]
The same mouse work reports reduced obesity and better insulin sensitivity in models of metabolic syndrome.[2]
Endurance and muscle claims: mice and cultured cells
Mice given SLU-PP-332 had more oxidative type IIa muscle fibres and better exercise endurance.[4]
In muscle cells grown from inactive women, the compound promoted myotube formation; this is a lab-dish result and not a treatment of people.[7]
Heart and ageing claims: mice
In mice with pressure-overload heart failure, the compound improved ejection fraction and survival.[3]
In aged mice, an 8-week course reversed age-related albuminuria, podocyte loss and inflammatory cytokines in the kidney.[5]
Athletes and the human evidence gap
A doping-control paper states that WADA prohibits the use of exercise mimetics and metabolic modulators in sports.[6]
A systematic review of the preclinical work concludes that clinical trials are still needed to confirm efficacy and safety in humans.[1]
A PubMed search on 2 Oct 2026 for SLU-PP-332 in title or abstract returned 10 records, and the cached studies behind this page are all in mice or cells.
Calculated from query "SLU-PP-332"[tiab]; date 2026-10-02; count 10; source web/src/data/evidence/slu-pp-332.json searches. Formula: count reported as recorded
More on SLU-PP-332
Common questions
Is SLU-PP-332 proven to work?
The strongest study we summarise for SLU-PP-332 is animal evidence, among 7 studies. That is not proof it works in people.
What does SLU-PP-332 do?
It is a synthetic agonist of the estrogen-related receptors alpha, beta and gamma, and mouse studies describe it as an exercise mimetic.[2]
What is SLU-PP-332 used for?
It is not approved for any use; the cached work calls it a candidate for metabolic disease, ageing and muscle conditions.[1]
More on SLU-PP-332
Sources
- 1[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
- 2A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 3Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Circulation · 2024PMID 37961903Accessed 2 Oct 2026
- 4Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
- 5Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
- 6Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
- 7Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
- 8PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.